Dr. Raúl Insa, SOM Biotech CEO, will be one of the speakers at the 4th International Congress on Research & Innovation in Neurodegenerative Diseases. This relevant event will take place at the EU Intellectual Property Office (EUIPO) in Alicante, Spain, from September 21-23, 2016. More than one hundred national and international experts will discuss the major advances in the…

SOM Biotech and the Anglo-Italian biotech accelerator Inorgen (www.inorgen.com) have successfully reached an agreement to co-develop drug repositioning programs focused mainly on rare diseases. Repositioning and rare diseases are two concepts widely known by both companies. By combining these concepts, costs and time needed to bring the drug onto the market is reduced. Safety risks are…

El Dr. Raúl Insa tomará parte en la XXXV edición de los Cursos de Veranos de la Universidad del País Vasco. Participará como ponente en la mesa redonda ‘Los retos científicos y económico-administrativos del desarrollo de terapias para las EERR’, la cual forma parte del curso LAS ENFERMEDADES RARAS: UN RETO GLOBAL PARA EL SISTEMA…

The ESADE Alumni Innovation Club and Alumni Entrepreneurship host the talk ''Five disruptive forms of healthcare innovation and enterprise'' on 24 May 2016. Dr. Raúl Insa, SOM Biotech CEO, will be one of the speakers. Five entrepreneurs and managers in the healthcare industry use ''disruptive innovation'' to differentiate their products and services in the market and thus achieve their goals…

SOM Biotech will attend next Bio International Convention 2016 in San Francisco, the world’s largest biotechnology event. The BIO attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking and partnering meetings to discover new opportunities and promising partnerships. You will find partnering opportunities, an outstanding education program, an…

TTR Amyloidosis Phase IIa results will be presented by Dr. Josep Gàmez at AAN 2016 Annual Meeting to be held in Vancouver (Canada) from 15th to 21th of April. This Clinical Trial has been performed by SOM Biotech and VHIR (Vall d'Hebron Hospital Institute of Research). Further information about the meeting at AAN 2016 Annual…